Harald Wajant

Josef Schneider Str. 2
Wuerzburg, BY 97080, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 114 publications

TNFR2-targeting biologics: Molecular mode of action, possible applications, and future developments.

TNFR2-targeting biologics: Molecular mode of action, possible applications, and future developments.

Journal: Journal of leukocyte biology

Published: October 04, 2025

Biofabrication of Endothelialized, Intrinsically Vascularized 3D-Printed Recombinant Spider Silk Scaffolds.

Biofabrication of Endothelialized, Intrinsically Vascularized 3D-Printed Recombinant Spider Silk Scaffolds.

Journal: Advanced healthcare materials

Published: October 02, 2025

A simple and broadly applicable nanobody-based approach to generate potent TNFR agonists.

A simple and broadly applicable nanobody-based approach to generate potent TNFR agonists.

Journal: Cell death & disease

Published: August 06, 2025

In Vivo Vascularization of Cell-Supplemented Spider Silk-Based Hydrogels in the Arteriovenous Loop Model.

In Vivo Vascularization of Cell-Supplemented Spider Silk-Based Hydrogels in the Arteriovenous Loop Model.

Journal: Biomimetics (Basel, Switzerland)

Published: December 06, 2024

Valence and avidity determine the agonistic activity of anti-TNFR2 nanobody fusion proteins.

Valence and avidity determine the agonistic activity of anti-TNFR2 nanobody fusion proteins.

Journal: Cell chemical biology

Published: November 30, 2024

Two subsets of regulatory CD8+ T cells with differential transcriptome revealed by single cell analysis.

Two subsets of regulatory CD8+ T cells with differential transcriptome revealed by single cell analysis.

Journal: iScience

Published: October 18, 2024

TRAF2 and RIPK1 redundantly mediate classical NFκB signaling by TNFR1 and CD95-type death receptors.

TRAF2 and RIPK1 redundantly mediate classical NFκB signaling by TNFR1 and CD95-type death receptors.

Journal: Cell death & disease

Published: April 30, 2024

A Novel Tetravalent CD95/Fas Fusion Protein With Superior CD95L/FasL Antagonism.

A Novel Tetravalent CD95/Fas Fusion Protein With Superior CD95L/FasL Antagonism.

Journal: Proteins

Published: March 09, 2024

Genetically engineered IgG1 and nanobody oligomers acquire strong intrinsic CD40 agonism.

Genetically engineered IgG1 and nanobody oligomers acquire strong intrinsic CD40 agonism.

Journal: Bioengineered

Published: January 12, 2024

Corrigendum: A TNFR2-specific TNF fusion protein with improved in vivo activity.

Corrigendum: A TNFR2-specific TNF fusion protein with improved in vivo activity.

Journal: Frontiers in immunology

Published: December 08, 2023

Editorial: TNFRSF agonists: mode of action and therapeutic opportunities.

Editorial: TNFRSF agonists: mode of action and therapeutic opportunities.

Journal: Frontiers in immunology

Published: October 26, 2023

Systemic treatment with a selective TNFR2 agonist alters the central and peripheral immune responses and transiently improves functional outcome after experimental ischemic stroke.

Systemic treatment with a selective TNFR2 agonist alters the central and peripheral immune responses and transiently improves functional outcome after experimental ischemic stroke.

Journal: Journal of neuroimmunology

Published: September 20, 2023

Showing 1-12 of 114

Last Updated: 09/26/2026